Matinas BioPharma Holdings, Inc. (MTNB) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.39
↓-86% vs avg
5yr avg: 2.79
30Y Low0.3·High11.3
ROE
↓
-180.7%
↑-128% vs avg
5yr avg: -79.3%
30Y Low-220%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MTNB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Matinas BioPharma Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $2M | $47M | $108M | $212M | $268M | $330M | $58M | $105M | $81M | $44M |
| Enterprise Value | $-825741 | $-1908427 | $46M | $106M | $196M | $259M | $312M | $46M | $98M | $77M | $41M |
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 42.86 | 34.00 | 6432.73 | 1691.22 | 3669.81 | 487.44 | 701.14 | — | 224.99 |
| P/B Ratio | 0.39 | 0.33 | 2.44 | 2.96 | 4.04 | 4.20 | 9.97 | 3.62 | 9.83 | 11.29 | 7.21 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MTNB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 41.74 | 33.14 | 5937.97 | 1636.39 | 3470.06 | 386.77 | 654.09 | — | 208.45 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MTNB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -771.3% to -2168.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -180.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | -423.1% | -44090.9% | -8968.8% | -12409.0% | -5568.0% | -5919.6% | — | -2621.0% |
| Operating Margin | — | — | -2168.4% | -771.3% | -74954.5% | -15288.4% | -21067.4% | -12230.9% | -11024.6% | — | -5096.0% |
| Net Profit Margin | — | — | -2093.2% | -658.6% | -70554.5% | -14177.0% | -19343.4% | -11760.4% | -10345.9% | — | -4697.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -180.7% | -180.7% | -82.1% | -47.1% | -40.1% | -46.4% | -70.6% | -105.0% | -173.7% | -114.9% | -220.1% |
| ROA | -128.5% | -128.5% | -44.1% | -30.0% | -35.2% | -40.4% | -57.7% | -82.0% | -127.8% | -83.4% | -155.3% |
| ROIC | -173.9% | -173.9% | -68.7% | -52.7% | -40.7% | -51.8% | -147.8% | -284.4% | -362.5% | -204.9% | -582.2% |
| ROCE | -151.5% | -151.5% | -49.0% | -37.4% | -39.8% | -46.3% | -69.8% | -100.0% | -160.4% | -105.5% | -208.2% |
MTNB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.38 | 0.18 | 0.11 | 0.09 | 0.06 | 0.13 | 0.02 | 0.02 | 0.02 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.58 | -0.06 | -0.08 | -0.31 | -0.14 | -0.54 | -0.75 | -0.66 | -0.55 | -0.53 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($7M) exceeds total debt ($3M)
MTNB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Matinas BioPharma Holdings, Inc.'s current ratio of 3.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.06x to 3.01x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.01 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 | 3.15 |
| Quick Ratio | 3.01 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 3.58 | 3.16 | 3.15 |
| Cash Ratio | 2.73 | 2.73 | 5.25 | 6.72 | 11.41 | 16.45 | 8.97 | 4.38 | 3.28 | 2.84 | 2.86 |
| Asset Turnover | — | — | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | — | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
MTNB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Matinas BioPharma Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| Shares Outstanding | — | $5M | $4M | $4M | $4M | $4M | $3M | $2M | $2M | $1M | $1M |
Peer Comparison
Compare MTNB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MTNBYou | $4M | -0.1 | — | — | — | — | -180.7% | -173.9% | — |
 ARQT | $3B | -201.6 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 GILD | $154B | 18.3 | 11.8 | 16.2 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 PTCT | $7B | 10.2 | 6.8 | 9.3 | 95.9% | 49.5% | — | — | 0.5 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 IDYA | $3B | -24.4 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 AGIO | $2B | -4.8 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
MTNB — Frequently Asked Questions
Quick answers to the most common questions about buying MTNB stock.
What is Matinas BioPharma Holdings, Inc.'s P/E ratio?
Matinas BioPharma Holdings, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Matinas BioPharma Holdings, Inc.'s ROE?
Matinas BioPharma Holdings, Inc.'s return on equity (ROE) is -180.7%. The historical average is -103.4%.
Is MTNB stock overvalued?
Based on historical data, Matinas BioPharma Holdings, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.